

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711 F: 844.513.1522 W: fresenius-kabi.ca

August 11, 2022

## Sodium Chloride Injection, USP Supply Update

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that our Sodium Chloride Injection, USP 4mEq/mL SD Vial 30 mL and Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL will be available across all distribution centres by August 15, 2022. Once available, these products will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status August	Supply Status September
02139510	C918930	975916	158460	Sodium Chloride Injection, USP 4mEq/mL SD Vial 30 mL	On 100% allocation effective Aug. 15, 2022	On 100% allocation
02139510	C88B2	922869	594234	Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL	On 100% allocation effective Aug. 15, 2022	Effective Sep. 1, 2022, allocations increased to cover 100% of 200 mL demand plus 100% of 100 mL demand.

We regret to advise that due to production delays, we will be encountering a supply interruption on our **Sodium** Chloride Injection, USP 4mEq/mL Maxivial® 100 mL effective September 1, 2022 until November 1, 2022.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Estimated Stockout Date*	Estimated Availability Date
02139510	C88B1	922857	594309	Sodium Chloride Injection, USP 4mEq/mL Maxivial® 100 mL	Sep. 1, 2022	Nov. 1, 2022

\*Please note that the stockout date may vary by region, please check your local distribution centre for availability.

Effective September 1, 2022 allocations for our Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL will be increased. Contract customers will be allocated 100% of historical monthly 200 mL demand, plus 100% of historical monthly 100 mL demand.

We recognize the difficulties and inconvenience that you may encounter as a result of our supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

George Shamsoun Associate Director – Marketing, IV Drugs george.shamsoun@fresenius-kabi.com